Development of a novel estimation method for hemoglobin A1c using glycated albumin in type 2 diabetes mellitus patients with end-stage renal disease

Akihiko Nakamura, Ryo Kodera, Noriko Sakamoto, Haruyo Ujike, Jun Wada, Kenichi Shikata, Hirofumi Makino

Research output: Contribution to journalArticle

Abstract

Aim: We developed a novel estimation method for hemoglobin A1c (HbA1c) in type 2 diabetes (T2D) patients with end-stage renal disease (ESRD). This method is based on the glycated albumin (GA) level. Methods: Of the 788 Japanese patients with T2D included in this study, 545 had normal renal function (NRF group) and 243 had ESRD. Oral glucose tolerance tests (OGTTs) were performed in 80 subjects. The variables GA, body mass index (BMI), hemoglobin (Hb), and estimated glomerular filtration rate (eGFR) were significantly associated with the GA-to-HbA1c ratio and were used to determine the estimated HbA1c (eHbA1c). One method of estimating HbA1c involved dividing GA by the GA-to-HbA1c ratio predicted from the estimated regression equation; the estimated HbA1c obtained in this manner was denoted eHbA1c-1. Results: eHbA1c-1 (%) = GA × [4.688 − 18.833 × GA−1 − 0.015 × BMI − 0.037 × Hb (− 0.002 × eGFR for patients without ESRD)]−1; adjusted R2 = 0.676 for actual HbA1c. The sensitivity of eHbA1c-1 was better than that of GA for diabetes diagnosis using the 75-g OGTT. There were no differences in the slope of eHbA1c-1 versus GA and the variance of eHbA1c-1 between the ESRD and NRF groups. eHbA1c-1 was not associated with Hb, erythropoiesis-stimulating agent use, or ESRD concomitance. Conclusions: eHbA1c-1 may be a useful parameter for estimating HbA1c in T2D patients with ESRD.

Original languageEnglish
Pages (from-to)179-188
Number of pages10
JournalDiabetology International
Volume9
Issue number3
DOIs
Publication statusPublished - Jul 1 2018

Fingerprint

Type 2 Diabetes Mellitus
Chronic Kidney Failure
Hemoglobins
Glucose Tolerance Test
glycosylated serum albumin
Hematinics
Glomerular Filtration Rate
Body Mass Index
Kidney

Keywords

  • End-stage renal disease
  • Glycated albumin
  • Hemoglobin A1c
  • Type 2 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Development of a novel estimation method for hemoglobin A1c using glycated albumin in type 2 diabetes mellitus patients with end-stage renal disease. / Nakamura, Akihiko; Kodera, Ryo; Sakamoto, Noriko; Ujike, Haruyo; Wada, Jun; Shikata, Kenichi; Makino, Hirofumi.

In: Diabetology International, Vol. 9, No. 3, 01.07.2018, p. 179-188.

Research output: Contribution to journalArticle

@article{bf0914b6a457407daedfca894a2ca748,
title = "Development of a novel estimation method for hemoglobin A1c using glycated albumin in type 2 diabetes mellitus patients with end-stage renal disease",
abstract = "Aim: We developed a novel estimation method for hemoglobin A1c (HbA1c) in type 2 diabetes (T2D) patients with end-stage renal disease (ESRD). This method is based on the glycated albumin (GA) level. Methods: Of the 788 Japanese patients with T2D included in this study, 545 had normal renal function (NRF group) and 243 had ESRD. Oral glucose tolerance tests (OGTTs) were performed in 80 subjects. The variables GA, body mass index (BMI), hemoglobin (Hb), and estimated glomerular filtration rate (eGFR) were significantly associated with the GA-to-HbA1c ratio and were used to determine the estimated HbA1c (eHbA1c). One method of estimating HbA1c involved dividing GA by the GA-to-HbA1c ratio predicted from the estimated regression equation; the estimated HbA1c obtained in this manner was denoted eHbA1c-1. Results: eHbA1c-1 ({\%}) = GA × [4.688 − 18.833 × GA−1 − 0.015 × BMI − 0.037 × Hb (− 0.002 × eGFR for patients without ESRD)]−1; adjusted R2 = 0.676 for actual HbA1c. The sensitivity of eHbA1c-1 was better than that of GA for diabetes diagnosis using the 75-g OGTT. There were no differences in the slope of eHbA1c-1 versus GA and the variance of eHbA1c-1 between the ESRD and NRF groups. eHbA1c-1 was not associated with Hb, erythropoiesis-stimulating agent use, or ESRD concomitance. Conclusions: eHbA1c-1 may be a useful parameter for estimating HbA1c in T2D patients with ESRD.",
keywords = "End-stage renal disease, Glycated albumin, Hemoglobin A1c, Type 2 diabetes",
author = "Akihiko Nakamura and Ryo Kodera and Noriko Sakamoto and Haruyo Ujike and Jun Wada and Kenichi Shikata and Hirofumi Makino",
year = "2018",
month = "7",
day = "1",
doi = "10.1007/s13340-018-0342-6",
language = "English",
volume = "9",
pages = "179--188",
journal = "Diabetology International",
issn = "2190-1678",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Development of a novel estimation method for hemoglobin A1c using glycated albumin in type 2 diabetes mellitus patients with end-stage renal disease

AU - Nakamura, Akihiko

AU - Kodera, Ryo

AU - Sakamoto, Noriko

AU - Ujike, Haruyo

AU - Wada, Jun

AU - Shikata, Kenichi

AU - Makino, Hirofumi

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Aim: We developed a novel estimation method for hemoglobin A1c (HbA1c) in type 2 diabetes (T2D) patients with end-stage renal disease (ESRD). This method is based on the glycated albumin (GA) level. Methods: Of the 788 Japanese patients with T2D included in this study, 545 had normal renal function (NRF group) and 243 had ESRD. Oral glucose tolerance tests (OGTTs) were performed in 80 subjects. The variables GA, body mass index (BMI), hemoglobin (Hb), and estimated glomerular filtration rate (eGFR) were significantly associated with the GA-to-HbA1c ratio and were used to determine the estimated HbA1c (eHbA1c). One method of estimating HbA1c involved dividing GA by the GA-to-HbA1c ratio predicted from the estimated regression equation; the estimated HbA1c obtained in this manner was denoted eHbA1c-1. Results: eHbA1c-1 (%) = GA × [4.688 − 18.833 × GA−1 − 0.015 × BMI − 0.037 × Hb (− 0.002 × eGFR for patients without ESRD)]−1; adjusted R2 = 0.676 for actual HbA1c. The sensitivity of eHbA1c-1 was better than that of GA for diabetes diagnosis using the 75-g OGTT. There were no differences in the slope of eHbA1c-1 versus GA and the variance of eHbA1c-1 between the ESRD and NRF groups. eHbA1c-1 was not associated with Hb, erythropoiesis-stimulating agent use, or ESRD concomitance. Conclusions: eHbA1c-1 may be a useful parameter for estimating HbA1c in T2D patients with ESRD.

AB - Aim: We developed a novel estimation method for hemoglobin A1c (HbA1c) in type 2 diabetes (T2D) patients with end-stage renal disease (ESRD). This method is based on the glycated albumin (GA) level. Methods: Of the 788 Japanese patients with T2D included in this study, 545 had normal renal function (NRF group) and 243 had ESRD. Oral glucose tolerance tests (OGTTs) were performed in 80 subjects. The variables GA, body mass index (BMI), hemoglobin (Hb), and estimated glomerular filtration rate (eGFR) were significantly associated with the GA-to-HbA1c ratio and were used to determine the estimated HbA1c (eHbA1c). One method of estimating HbA1c involved dividing GA by the GA-to-HbA1c ratio predicted from the estimated regression equation; the estimated HbA1c obtained in this manner was denoted eHbA1c-1. Results: eHbA1c-1 (%) = GA × [4.688 − 18.833 × GA−1 − 0.015 × BMI − 0.037 × Hb (− 0.002 × eGFR for patients without ESRD)]−1; adjusted R2 = 0.676 for actual HbA1c. The sensitivity of eHbA1c-1 was better than that of GA for diabetes diagnosis using the 75-g OGTT. There were no differences in the slope of eHbA1c-1 versus GA and the variance of eHbA1c-1 between the ESRD and NRF groups. eHbA1c-1 was not associated with Hb, erythropoiesis-stimulating agent use, or ESRD concomitance. Conclusions: eHbA1c-1 may be a useful parameter for estimating HbA1c in T2D patients with ESRD.

KW - End-stage renal disease

KW - Glycated albumin

KW - Hemoglobin A1c

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85049489593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049489593&partnerID=8YFLogxK

U2 - 10.1007/s13340-018-0342-6

DO - 10.1007/s13340-018-0342-6

M3 - Article

VL - 9

SP - 179

EP - 188

JO - Diabetology International

JF - Diabetology International

SN - 2190-1678

IS - 3

ER -